Last updated on April 2018

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis


Brief description of study

To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

Clinical Study Identifier: NCT02256150

Contact Investigators or Research Sites near you

Start Over

Asahi Kasei Pharma Corporation

Renji Hospital Shanghai Jiaotong University School of Medical
Shanghai, China

Asahi Kasei Pharma Corporation

Zhongshan Hospital Fudan University
Shanghai, China